II. Indications
III. Mechanism
- CD38 Antigen (Cyclic ADP Ribose Hydrolase)
- Cell surface enzyme expressed primarily on WBCs (esp. plasma cells, as well as B Cells, T Cells, Natural Killer Cells)
- CD38 catalyzes the reaction catalyzes the synthesis of cyclic ADP-Ribose (cADPR) from NAD+ and ADP-Ribose
- Cyclic ADP-Ribose is integral to intracellular Calcium level regulation
- CD38 also activates a second messenger system in cell signaling
- Appears to regulate cytotoxic response of activated Natural Killer Cells
- CD38 Monoclonal Antibody (e.g. Daratumumab)
- Monoclonal Antibody directed against the cell surface Glycoprotein CD-38
- Used to target Multiple Myeloma and plasma Leukemia cells
- Binding triggers anti-tumor cytotoxicity
IV. Medications
- Daratumumab (Darzalex) injection solution
V. Dosing
- See other references for disease specific dosing protocols
- Premedicate with Corticosteroids, antipyretics and Antihistamines
VI. Adverse Effects
- Infusion Reactions
- Cytopenia
- Other common adverse effects
- Peripheral Neuropathy
- Nausea
- Altered bowel habits (Constipation, Diarrhea)
- Peripheral Edema
- Dyspnea
VII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters, Pregnancy category X)
- Use reliable Contraception
- Monitoring
- Complete Blood Count with differential and Platelet Count
VIII. Drug Interactions
- Interferes with Red Blood Cell cross-matching and Antibody screening
- Type and screen prior to treatment
IX. Resources
Images: Related links to external sites (from Bing)
Related Studies
Definition (CSP) | membrane associated enzymes; converts NAD to cyclic ADP ribose; CD (2+) activates second messenger and ADP ribose. |
Definition (MSH) | A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS. |
Concepts | Amino Acid, Peptide, or Protein (T116) |
MSH | D051997 |
SnomedCT | 69832000 |
LNC | LP18354-8, LP95517-6, MTHU034406, MTHU022280 |
English | CD38 - Cluster of diff ag 38, Cluster of diff antigen 38, CD38 Antigen, ANTIGENS CD 038, CD 038 ANTIGENS, Antigens, CD38 [Chemical/Ingredient], cd38 antigen, CD38 molecule, CD38 Ag, CD38, Lymphocyte antigen CD38, CD38 - Cluster of differentiation antigen 38, Cluster of differentiation antigen 38, Leucocyte 17, OKT10 - Ortho Kung T10, Ortho Kung T10, T-cell lineage 10, T10 - T-cell lineage 10, Leukocyte 17, Lymphocyte antigen CD38 (substance), Antigen, T10, CD38 Antigens, CD38, ADPR Cyclase, Cyclase CD38, ADPR, Cyclase T10, ADPR, Lymphocyte Differentiation Antigen CD38, NIM R5 Antigen, NIM-R5 Antigen, ADPR Cyclase CD38, ADPR Cyclase T10, Acute Lymphoblastic Leukemia Cells Antigen CD38, T10 Antigen, Antigens, CD38 |
Czech | antigeny CD38 |
Finnish | CD38-antigeenit |
Russian | ANTIGENY CD38, CD38 ANTIGENY, CD38 АНТИГЕНЫ, АНТИГЕНЫ CD38 |
Japanese | 抗原-CD38, 抗原-T10, CD38抗原, T10抗原 |
Swedish | CD39-antigener |
French | Antigène CD38 de différentiation des lymphocytes, Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase 1, cADPr hydrolase 1, Antigènes CD38, Antigène CD38, Antigène T10, CD38, ADPR cyclase CD38, ADPR cyclase T10, Antigène CD38 de différentiation lymphocytaire |
Polish | Antygeny CD38 |
Spanish | antígeno linfocitario CD38 (sustancia), antígeno linfocitario CD38, Antígenos CD38 |
Portuguese | Antígenos CD38 |
German | ADPR-Cyclase CD38, ADPR-Cyclase T10, Antigene, CD38-, CD38-Antigene, CD38-Antigen, Lymphozyten-differenzierendes Antigen CD38, NIM-R5-Antigen, T10-Antigen |
Italian | Antigeni CD38 |
Ontology: Cyclic ADP-ribose Hydrolase (C0217585)
Definition (MSH) | EC 3.2.2.5 |
Concepts | Amino Acid, Peptide, or Protein (T116) , Enzyme (T126) |
MSH | D036541 |
English | cADPR hydrolase, ADP-ribose Hydrolase, Cyclic, Cyclic ADP ribose Hydrolase, Hydrolase, Cyclic ADP-ribose, Hydrolase, cADPR, cADPR Hydrolase, Cyclic ADP-ribose Hydrolase |
German | cADP-Ribose Hydrolase, zyklische-ADP-Ribose Hydrolase, cADPR-Hydrolase |
Ontology: daratumumab (C2346801)
Definition (NCI) | A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells. |
Concepts | Pharmacologic Substance (T121) |
MSH | C556306 |
English | Anti-CD38 Monoclonal Antibody, Daratumumab, daratumumab, JNJ-54767414, DARATUMUMAB |